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Postpartum thyroid dysfunction (PPTD) is a common disorder which causes considerable morbidity in aﬀected women. The
availability of eﬀective treatment for hypothyroid PPTD, the occurrence of the disease in subsequent pregnancies and the need
to identify subjects who develop long term hypothyroidism, has prompted discussion about screening for this disorder. There is
currentlynoconsensusaboutscreeningasinvestigationshithertohavebeenvariableintheirdesign,deﬁnitionsandassayfrequency
and methodology. There is also a lack of consensus about a suitable screening tool although thyroid peroxidase antibody (TPOAb)
is a leading contender. We present data about the use of TPOAb in early pregnancy and its value as a screening tool. Although its
positivepredictivevalueismoderate,itssensitivityandspeciﬁcitywhenusedinearlypregnancyarecomparableorbettercompared
to other times during pregnancy and the postpartum period. Recent studies have also conﬁrmed this strategy to be cost eﬀective
and to compare favourably with other screening strategies. We also explore the advantages of universal screening.
1. PostpartumThyroidDysfunctionIsCommon
Postpartum thyroid dysfunction (PPTD) is a common dis-
order which causes considerable morbidity in some women
[1]. The availability of eﬀective treatment particularly for
the symptomatic hypothyroid phase, and the awareness that
hypothyroidism is a long-term consequence in a signiﬁcant
minority of these subjects, has prompted discussion about
screening for PPTD [2, 3]. However, there is currently no
consensusbecauseofunresolvedissuesaboutaneﬀectiveand
sensitive prediction tool.
The current worldwide pooled prevalence for PPTD
is estimated to be 8% (95% CI 7.8–8.2%), with regional
variations—USA 5.7%, Asia 4.4%, Spain 9.3%, Sweden
7.3%, and The Netherlands 6.3% [4]. These diﬀerences may
be due to (a) variable study design (timing and number
of thyroid tests), (b) deﬁnition of PPTD, (c) prevalence of
thyroid peroxidase antibody (TPOAb), (d) assay methods
used (antimicrosomal versus TPOAb), and (e) population
characteristics (including prevalence of type 1 diabetes
mellitus (T1DM), PPTD in previous pregnancies, iodine
intake and genetics) [5].
The early hyperthyroid phase of PPTD causes minimal
symptoms and hardly ever requires speciﬁc treatment.
However, the hypothyroid phase which occurs later often
needs to be treated with thyroxine for up to 9 months [6]. A
signiﬁcant number of subjects who have hypothyroid PPTD
remain so at the end of the ﬁrst postpartum year and require
long-term thyroxine replacement [7–10].
2. The Rationale for Screeningfor PPTD
There are strong proponents on both sides of the thyroid
screening in pregnancy debate [3, 11, 12]. The Endocrine
Society currently recommends selective screening of high-
risk individuals only [13]. However, Vaidya et al. elegantly
demonstrated that screening of high-risk individuals alone
would miss 30% of hypothyroid and 69% of hyperthyroid
pregnant women [14]. A recent randomised controlled trial2 Journal of Thyroid Research
[15]andanotherstudy[16]conﬁrmedthisinitialimpression
about selective screening.
Those who advocate screening for PPTD cite the follow-
ing reasons in support of their argument:
(a) avoiding morbidity associated particularly with
hypothyroid PPTD,
(b) predicting the need for long-term thyroxine treat-
ment at the end of the ﬁrst postpartum year,
(c) identifying subjects who might develop PPTD in
subsequent pregnancies,
(d) identifying subjects for followup to detect long-term
hypothyroidism several years from initial diagnosis
[10, 17].
3. The Role of TPOAb in
Pregnancy-AssociatedMorbidity
The prevalence of microsomal and TPOAb in pregnant
women varies between 2.8 and 19.6% worldwide [18],
and a recent pooled prevalence from published data was
estimated to be 15.3–16% [4]. Although its role in causing
PPTD remains speculative, the presence of TPOAb identiﬁes
a subset of pregnant women who have a higher risk of
developing PPTD [4, 19]. In addition, TPOAb also identiﬁes
women who have a higher risk of long-term hypothyroidism
after PPTD [10, 17, 20, 21].
The presence of TPOAb during pregnancy is also asso-
ciated with miscarriage and preterm delivery [6], an IQ
decrement in children of even euthyroid mothers [22], and
postpartum psychiatric morbidity [23, 24]. The mechanisms
for these remain unclear.
4. A ScreeningTool for PPTD
The clinical utility of a screening tool depends on several
factors. It needs to be sensitive with a high positive predictive
value (to detect every subject with the condition if possible),
easy to perform (using uncomplicated technology), cheap
(so that widespread use is cost-beneﬁcial), and harmless to
the subject tested.
5. TPOAb asa ScreeningTool
Some authorities recommend TPOAb as a suitable screening
toolforPPTD[4,25].TherelativehighprevalenceofTPOAb
in early pregnancy, its easy measurement with current assays,
and its role as a risk marker for PPTD and long-term
hypothyroidism have been cited in its favour as discussed
above. Although earlier assays measured microsomal anti-
bodies, more recent assays measure antibodies to its speciﬁc
antigen, thyroid peroxidase, that is, TPOAb. Sensitive assays
for TPOAb which are relatively cheap to perform are now
available commercially and are in use worldwide [26, 27].
5.1. TPOAb and PPTD
5.1.1. Noninterventional Studies. An extensive analysis of
published data by Nicholson et al. examined the prevalence
of TPOAb and the risk of developing PPTD in these subjects.
They estimated a pooled prevalence of TPOAb of 16.2% and
a risk ratio of 5.7 for the development of PPTD (Table 1)[ 4].
A closer examination of these data helps us understand
why it is diﬃcult to reach a consensus about the use of
TPOAb for screening, despite favourable epidemiological
and statistical evidence.
(i) Several of these studies measured antimicrosomal
antibodies as this was acceptable practice at the
time.However,followingtheidentiﬁcationofthyroid
peroxidase (TPO) as the incriminating antigen, more
recent studies have used a TPOAb assay.
(ii) Furthermore, these antibodies were tested at variable
points during pregnancy and postpartum. We con-
tend that, for a prediction tool to be useful, it needs
to be used well in advance of the predicted event
that is, early pregnancy in this instance. Although
the risk ratios appear to be higher when postpartum
testing is done, we feel an early antepartum test
w o u l db em o r ep r a g m a t i c( Table 2). The immune
modulation of pregnancy and its eﬀect on TPOAb
(signiﬁcant decrease in levels as pregnancy advances
and a rebound increase postpartum) need to be
understood and taken into account.
(iii) The deﬁnitions of PPTD were variable in these
studies.
(iv) There is also a signiﬁcant variability of the popula-
tions studied. There may well have been a diﬀerence
in factors known to increase the risk of PPTD which
were not uniformly reported—iodine intake, genetic
predisposition to thyroid disease, demographic and
behavioural characteristics (age, parity, smoking,
gender of oﬀspring, etc.), prevalence of type 1
diabetes mellitus, a history of PPTD in previous
pregnancies, and a family history of thyroid disease.
(v) There is no clear indication of the length of followup
in these studies either—raising the possibility of
missing some PPTD subjects.
Although extrapolating from these studies to a general pop-
ulation is not wise, we do not feel that the utility of TPOAb,
when used appropriately as a screening tool, is signiﬁcantly
diminished.
Since then, other investigators have also studied this
relationship. Diaz et al. found a 44% prevalence of TPOAb
in 25 subjects (out of 157) who developed PPTD [28]. Only
4.5% had TPOAb in the group who did not develop PPTD
(P = .001). Filippi et al. found a combined prevalence of
TPOAb and antithyroglobulin antibodies (TgAb) of 9.3%
and 28/43 (65.1%) had developed thyroid dysfunction at the
end of the ﬁrst year [29].
An earlier analysis of published data has shown that the
sensitivity, speciﬁcity, and positive predictive value (PPV) ofJournal of Thyroid Research 3
Table 1: TPOAb prevalence and the risk of developing PPTD (adapted from [4] with permission).
Author (number of
subjects in study)
Number/% prevalence of
TPOAb (95% CI)
Number with
PPTD
TPOAb +ve
with PPTD
Risk ratio for PPTD in TPOAb
+ve subjects (95% CI)
Shahbazian (1040) 248/24 (21–26) 119 73 5 (4–7)
Kent (718) 86/12 (10–14) 86 55 13 (9–19)
Furlanetto (284) 13/5 (3–8) 12 2 4 (0.9–15)
Lucas (579) No information 45 30 —
Kuijpens (291) 31/14 (11–19) 15 10 17 (6–46)
Lervang (591) 38/6 (5–9) 23 20 97 (30–312)
Jansson (460) 44/10 (7–13) 30 23 31 (14–68)
Dahlberg (224) 11/4.9 (2.1–7.7) 12 11 58 (18.2–184.9)
Amino (507) 62/12 (10–15) 28 25 59 (18.6–192)
Totals (4914) 586 419 279
Pooled estimate 16.2% (16–16.4) 5.7 (5.3–6.3)
Table 2: TPOAb and its utility for screening for PPTD: timing of
screening and sensitivity, speciﬁcity, and PPV (adopted from [25]
with permission).
Time of screening Sensitivity Speciﬁcity PPV
Early pregnancy 0.67–1 0.62–0.93 0.31–0.55
3rd trimester 0.71 0.92 0.52
Delivery/early postpartum 0.45–0.89 0.91–0.97 0.4–0.73
Late postpartum 0.46–0.86 0.9–0.98 0.53–0.78
TPOAb as a prediction tool are widely variable and depend
on the time of testing amongst other factors (Table 2)[ 25].
5.1.2. Interventional Studies. Several interventional studies
also have strengthened our knowledge about the role of
TPOAb in morbidity associated with pregnancy and PPT.
In one study, the administration of thyroxine to euthyroid
women with TPOAb signiﬁcantly reduced the risk of mis-
carriage [30]. A more recent well designed, randomised
placebo-controlled study elegantly showed that giving sele-
nium to pregnant women signiﬁcantly reduced postpartum
TPOAb titres and the incidence of PPTD [31]. These eﬀects
of selenium may be mediated through selenoenzymes which
are abundant in the thyroid gland [32]. Although these
studies do not prove a causative role, they further clarify the
relationship of TPOAb to pregnancy outcomes and PPTD.
5.2. TPOAb and Long-Term Thyroid Dysfunction after PPTD.
The presence of TPOAb in pregnancy is also a marker for
long-term thyroid dysfunction [5]. A recently published 12-
yearfollow-upstudycomparingwomenwhohadPPTDwith
controls found odds ratios for the risk of hypothyroidism
of 4.8 for PPTD, 9.7 for hypothyroid PPTD, and 51.4 for
TPOAb in association with hypothyroid PPTD [10]. This
increased risk is broadly in line with 2 previous studies
in which TPOAb-positive women who had PPTD were
followed up for a mean period of 60 and 78 months.
These investigators found hypothyroidism in 26% [33]a n d
46% [17], respectively, which were signiﬁcantly higher in
comparison to TPOAb negative controls. The relationship of
the hypothyroid phase of PPTD to the development of long-
term hypothyroidism cannot be over-emphasized, and this is
a consistent feature of studies published so far.
5.3. Timing of Screening. Although PPV remains only mod-
eratelyhigh,earlypregnancy(ﬁrsttrimester)screeningseems
to confer the highest sensitivity and speciﬁcity [25]. Early
pregnancy screening would seem highly pragmatic in a
screening programme too.
5.4. Cost Beneﬁt. A recent study found screening pregnant
women in the ﬁrst trimester with TPOAb to be cost-eﬀective
and to compare favourably with other screening strategies
currently in use [34]. These data supported previous evi-
dence from other investigators [35].
However, there are two objections to using TPOAb as a
screening tool based on the current data.
(a) No consensus can be achieved of its utility in screen-
ing because of the heterogeneity of the reported
studies—opponents of screening often quote the
diﬃculty in interpreting and extrapolating results
of published studies because of a high degree of
variability (see comments above).
(b) The occurrence of PPTD in antibody-negative sub-
jects also detracts from its value as a screening
tool—there are several studies where PPTD has
been reported in TPOAb-(or microsomal antibody)
negative subjects [10, 36, 37]. The reasons for this
are speculative—insensitivity of assays used to detect
TPOAb, the presence of TgAb only, sampling time
during pregnancy, population characteristics, and so
forth.
6.TPOAb Combined withClinicalData
Some investigators have studied the utility of TPOAb
combined with clinical features in predicting PPTD. Da
Costa et al. recruited 98 unselected women at 9–12 weeks
of pregnancy and followed them up for 1 year after delivery.4 Journal of Thyroid Research
TPOAbwaspresentin10.2%(95%CI4.1–16.3%)andPPTD
developed in 10.2% (95% CI 4.1–16.3%). A goitre in early
pregnancy and TPOAb were signiﬁcantly associated with
PPTD (P = .01, .001, resp.) [38]. The sensitivity (60%, 95%
CI 31.3–83.2) and speciﬁcity (95.5%, 95% CI 88.9–98.2%)
compared with data reported in earlier studies (Table 2).
But the PPV increased from 60 to 82.4% when goitre and
familyhistoryofthyroiddiseasewereaddedtoTPOAbasrisk
factors. Others have indicated the importance of ultrasound
echogenicity in predicting long-term thyroid dysfunction
following PPTD [17], and the importance of other ante-
natal indices needs to be conﬁrmed and their clinical utility
determined [39, 40].
7. Conclusions
The question of screening for PPTD is intimately linked
with the broader issue of screening for thyroid dysfunction
in pregnancy [41]. We have concentrated on the former
for this review. Experts and expert societies take a variable
stance on the question of screening in pregnancy, but there
is broad consensus about its advantages. Most advocate
targeted screening but numerous studies have indicated the
futility of this approach as a signiﬁcant number of aﬀected
women with thyroid dysfunction will fail to be identiﬁed
[14–16].
PPTD is a common condition causing signiﬁcant mor-
bidity. Screening for PPTD is safe and has many beneﬁts and
few disadvantages (maternal anxiety is mentioned frequently
in this regard). Its early detection may improve quality of life
and reduce morbidity in subsequent pregnancies and in the
long term. Cost beneﬁt analyses have demonstrated deﬁnite
cost advantages in screening.
TPOAb is a good screening tool and has been examined
by many investigators for predicting PPTD. Although there
are limited data of the beneﬁts of intervention in TPOAb-
positive women in early pregnancy [30, 31], such a paucity
of data should not deter us from recommending a screening
strategy using it. TPOAb in early pregnancy (ﬁrst trimester)
using a currently available sensitive assay seems to be the best
available tool at present despite all its imperfections. What
about women who are TPOAb negative but still develop
PPTD? There is no clear explanation for PPTD in these
women but this should not prevent clinicians from adopting
a screening strategy using TPOAb where the majority who
would develop PPTD would be identiﬁed.
The question about targeted or universal screening
continues to be debated. Given the current evidence of the
ineﬀectiveness of targeted screening in identifying all women
with thyroid dysfunction during pregnancy and the lack
of clarity of expert advice, we would advocate universal
screening. We believe adopting such a stance could only be
useful and its beneﬁts could then be examined in future
studies.
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